Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane Hydrochloride in Treating Young Patients With Relapsed or Refractory Solid Tumors, Lymphoma, or Leukemia

This study has been terminated.
Information provided by (Responsible Party):
National Cancer Institute (NCI) Identifier:
First received: July 7, 2009
Last updated: April 30, 2014
Last verified: April 2013
No Study Results Posted on for this Study
  Study Status: This study has been terminated.
  Study Completion Date: April 2013
  Primary Completion Date: April 2013 (Final data collection date for primary outcome measure)
Publications automatically indexed to this study by Identifier (NCT Number):